Suven Life Sciences has received a product patent each from Eurasia and Norway corresponding to NCEs (new chemical entities) for treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2034 and 2026 respectively, the company said on Wednesday. The granted claims include the class of selective 5-HT6 compounds that are being developed as therapeutic agents and useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, ADHD (Attention deficient hyperactivity disorder), Huntington’s disease, Parkinson and Schizophrenia. Suven has a pipeline of molecules in the CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally, CEO Venkat Jasti said.